Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 26, 2022 (5 years ago)

Meloxicam Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Meloxicam Tablets, USP, 15 mg, 1000 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd., Kurkumbh, India; Manufactured for: Cipla USA, Inc., 9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156. NDC: 69097-159-15

Affected NDC 69097-0159-15

Compare with the code on your package — it is the most precise check available.

Drug: Meloxicam Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Meloxicam
NDC 69097-0159
15 mg/1 Tablet
Oral
Cipla USA Inc. Rx
Recalling firm
Cardinal Healthcare
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0190-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Meloxicam recalls

See all
Class III · Low risk

Zynrelef (bupivacaine and meloxicam)

Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit

Terminated Packaging defect Heron Therapeutics, INC. NDC 47426-301-02 D-1335-2022
Class II · Moderate risk

Meloxicam Tablets

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 69097-158-07 D-0463-2021
Class III · Low risk

Mobic (meloxicam)

Labeling: Incorrect or missing package insert. One lot of Mobic Tablets is packaged with an incorrect insert.

Terminated Labeling / mix-up Boehringer Ingelheim Pharmaceuticals, Inc. NDC 0597-0030-01 D-0007-2018
Class II · Moderate risk

All lidocaine

Lack of Processing Controls

Terminated cGMP deviation Reliable Rexall-A Compounding Pharmacy D-1103-2016
Class II · Moderate risk

Meloxicam capsules

Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin.

Terminated Cross-contamination South Coast Specialty Compounding, Inc. D-1339-2015

Other recalls by Cardinal Healthcare

All 2022 recalls
Class II · Moderate risk

Inhub Wixela

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0202-2024
Class II · Moderate risk

Warfarin Sodium Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0201-2024
Class II · Moderate risk

Warfarin Sodium Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0200-2024